This inventor holds 3 USPTO granted patents and 7 published patent applications. Top assignee: Tempus Labs, Inc.. Active years: 2021-2022.
Company Filing History:
Years Active: 2021-2022
Title: Terri M Driessen: Innovator in Liquid Biopsy Technology
Introduction
Terri M Driessen is a prominent inventor based in Chicago, IL (US). She has made significant contributions to the field of liquid biopsy technology, holding a total of 3 patents. Her work focuses on improving methods for cancer diagnostics through innovative approaches in genetic analysis.
Latest Patents
Terri's latest patents include groundbreaking methods and systems for dynamic variant thresholding in a liquid biopsy assay. This invention provides a framework for validating somatic sequence variants in cancer patients by analyzing cell-free DNA fragments. The process involves aligning sequence reads to a reference sequence and comparing variant allele fragment counts against a dynamic threshold based on pre-test odds. This innovation enhances the accuracy of cancer diagnostics by validating or rejecting somatic sequence variants based on robust statistical methods.
Another notable patent by Terri is focused on refining copy number variation in a liquid biopsy assay. This invention utilizes a first dataset comprising bin-level and segment-level sequence ratios to validate copy number status annotations. By applying various filters to the dataset, the method ensures that only accurate annotations are accepted, thereby improving the reliability of liquid biopsy results.
Career Highlights
Terri M Driessen currently works at Tempus Labs, Inc., a company dedicated to advancing precision medicine through data-driven insights. Her role at Tempus Labs allows her to leverage her expertise in liquid biopsy technology to contribute to innovative cancer diagnostics.
Collaborations
Throughout her career, Terri has collaborated with notable colleagues, including Wei Zhu and Robert Tell. These partnerships have fostered a collaborative environment that enhances the development of cutting-edge technologies in the field of oncology.
Conclusion
Terri M Driessen is a trailblazer in the realm of liquid biopsy technology, with her patents paving the way for advancements in cancer diagnostics. Her contributions are vital in the ongoing quest for more accurate and efficient methods to detect and validate genetic variations in cancer patients.